Clinical trials: Prostate Cancer Patients
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
This is an open label randomized phase II study for prostate cancer patients who have disease progression after hormonal therapy.
- Conditions
- Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
- Trial name
- NCT01313559
- Testing
- Pasireotide, Everolimus, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Solid Tumor, Glioblastoma Multiforme
A Trial of Ipatasertib in Combination With Atezolizumab
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B).
- Conditions
- Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
- Trial name
- IceCAP (NCT03673787)
- Testing
- ipatasertib, Atezolizumab
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Adenocarcinoma
Prostate Cancer - Localized Adenocarcinoma Proton Therapy
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma
- Trial name
- NCT03285815
- Testing
- Proton Therapy
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- National Cancer Center, Korea
Prostate Cancer Patients
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
- Trial name
- NCT04664725
- Testing
- Repaglinide, Bupropion and SHR3680
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT02012920
- Testing
- Seviteronel: given orally once daily in 28 day cycles
- Where
- 23 sites in United States, Greece and 2 more
- Volunteers
- 200 people
- Sponsor
- Innocrin Pharmaceutical
Prostatic Neoplasms, Neoplasm Metastasis
Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients
For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery.
- Trial name
- NCT04790968
- Testing
- PSMA-PET, PSMA-PET/MRI, PSMA-PET/CT
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
This phase II pilot trial studies how well bicalutamide and raloxifene hydrochloride work in treating patients with prostate cancer undergoing surgery.
- Trial name
- NCT03147196
- Testing
- Bicalutamide, Laboratory Biomarker Analysis, Questionnaire Administration
- Sponsor
- Mayo Clinic
Prostate Cancer
Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.
Prostate cancer (PCa) is the most common cancer and the third leading cause of cancer-related death among men in France. Active surveillance is one of the management options for low-risk prostate cancer.
- Trial name
- ANCAPRO (NCT07351461)
- Testing
- Patient on active surveillance
- Where
- France
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy
RATIONALE: Diindolylmethane may slow the growth of prostate cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of diindolylmethane in treating patients with nonmetastatic prostate cancer that has…
- Trial name
- NCT00305747
- Testing
- BR-DIM
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.
- Trial name
- NCT02107391
- Testing
- Dendritic Cells DCVAC/PCa, Leuprolide acetate, Goserelin Acetate
- Where
- 9 sites in Czechia
- Volunteers
- 63 people
- Sponsor
- SOTIO a.s.
Prostate Cancer
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the…
- Trial name
- NCT01961713
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer, Other Solid Tumors
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with…
- Conditions
- Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
- Trial name
- NCT06926283
- Testing
- DXC008
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Prostate or Bladder Cancer
Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.
Pelvic lymph node dissection (PLND) is the most accurate staging tool to determine lymph node involvement in prostate and bladder cancer.
- Trial name
- NCT02001857
- Testing
- 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- University Hospital, Ghent
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Metastatic Prostate Cancer
Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer
This is a Phase I/IIa study evaluating the safety and feasibility of [89Zr]Df-IAB2M as an immunoPET tracer for metastatic prostate cancer.
- Trial name
- IAB2M (NCT01923727)
- Testing
- [89Zr]Df-IAB2M
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- ImaginAb, Inc.
Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who…
- Trial name
- ARTISAN (NCT07214961)
- Testing
- AB001
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ARTBIO Inc.
Prostate Cancer, Prostatectomy
Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function
1. STUDY PURPOSE: Robot-assisted surgery for prostate cancer aims to remove the tumor while preserving the delicate nerves that control erections (called "nerve-sparing" surgery).
- Conditions
- Prostate Cancer, Prostatectomy, Robotic Surgery, Erectile Function
- Trial name
- SPARE-EF (NCT07747272)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Florence